Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys
Authors
Keywords
-
Journal
mAbs
Volume 8, Issue 5, Pages 969-982
Publisher
Informa UK Limited
Online
2016-04-26
DOI
10.1080/19420862.2016.1178435
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Macrophages: Development and Tissue Specialization
- (2015) Chen Varol et al. Annual Review of Immunology
- Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
- (2015) Mario Dicato et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- The coming of age of engineered multivalent antibodies
- (2015) Natalia Nuñez-Prado et al. DRUG DISCOVERY TODAY
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation
- (2015) Yang Shen et al. mAbs
- Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics
- (2015) Amita Datta-Mannan et al. mAbs
- Alternative molecular formats and therapeutic applications for bispecific antibodies
- (2015) Christoph Spiess et al. MOLECULAR IMMUNOLOGY
- Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
- (2015) Angela Schoch et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Scavenger Receptor Structure and Function in Health and Disease
- (2015) Izma Zani et al. Cells
- Fc -receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments
- (2014) R. P. Taylor et al. BLOOD
- Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge
- (2014) Bing Li et al. mAbs
- Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
- (2013) Brian Gurbaxani et al. MOLECULAR IMMUNOLOGY
- The scavenger endothelial cell: a new player in homeostasis and immunity
- (2012) Karen Kristine Sørensen et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition
- (2012) Rebecca Croasdale et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Optimization of Multivalent Bispecific Antibodies and Immunocytokines with Improved in Vivo Properties
- (2012) Edmund A. Rossi et al. BIOCONJUGATE CHEMISTRY
- Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors
- (2012) Y. Xin et al. CLINICAL CANCER RESEARCH
- A strategy for risk mitigation of antibodies with fast clearance
- (2012) Isidro Hötzel et al. mAbs
- A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance
- (2012) P. J. Yazaki et al. PROTEIN ENGINEERING DESIGN & SELECTION
- A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity
- (2011) Jianying Dong et al. mAbs
- Engineering the variable region of therapeutic IgG antibodies
- (2011) Tomoyuki Igawa et al. mAbs
- Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species
- (2011) Yulia Vugmeyster et al. PHARMACEUTICAL RESEARCH
- Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
- (2010) C. Andrew Boswell et al. BIOCONJUGATE CHEMISTRY
- Translational Pharmacokinetics and Pharmacodynamics of an FcRn-Variant Anti-CD4 Monoclonal Antibody From Preclinical Model to Phase I Study
- (2010) Y Zheng et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Charge variants in IgG1
- (2010) Leslie A. Khawli et al. mAbs
- Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
- (2010) Tomoyuki Igawa et al. NATURE BIOTECHNOLOGY
- Reduced elimination of IgG antibodies by engineering the variable region
- (2010) T. Igawa et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma
- (2009) E. A. Rossi et al. BLOOD
- Impact of Molecular Processing in the Hinge Region of Therapeutic IgG4 Antibodies on Disposition Profiles in Cynomolgus Monkeys
- (2009) K. Stubenrauch et al. DRUG METABOLISM AND DISPOSITION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now